Related Experiment Video

Updated: Oct 12, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine

Y Tsurumi1, H Nagashima, K Ichikawa

  • 1Department of Cardiology, Heart Institute of Japan, Tokyo, Japan.

Journal of the American College of Cardiology
|November 1, 1995
PubMed

Insights

Elevated lipoprotein(a) [Lp(a)] impairs coronary artery vasodilation, even without visible atherosclerosis. This suggests Lp(a) causes endothelial dysfunction, contributing to future coronary artery disease risk.

Area of Science:

  • Cardiovascular Research
  • Endothelial Function Studies
  • Lipoprotein Analysis

Background:

  • Epidemiologic studies link elevated plasma lipoprotein(a) [Lp(a)] to increased coronary artery disease risk.
  • Coronary risk factors impact endothelium-dependent vasomotion.
  • The specific influence of Lp(a) on coronary vasomotor function remained undetermined.

Purpose of the Study:

  • To investigate the impact of plasma lipoprotein(a) [Lp(a)] levels on coronary endothelial vasomotor function.
  • To determine if Lp(a) affects the ability of coronary arteries to dilate or constrict.

Main Methods:

  • Quantitative coronary angiography was used to assess left anterior descending coronary artery diameter changes.
  • Intracoronary acetylcholine and isosorbide dinitrate were administered to evaluate vasomotion.
  • Plasma Lp(a) levels were quantified using enzyme-linked immunosorbent assay in 30 patients with normal coronary arteries.

Main Results:

  • A significant inverse correlation was observed between plasma Lp(a) levels and acetylcholine-induced vasomotion across all segments of the left anterior descending coronary artery (p < 0.01).
  • Plasma Lp(a) was identified as a significant predictor of vasomotion in response to acetylcholine.
  • Vasomotor responses varied, with Lp(a) inversely correlating with the degree of vasodilation/constriction.

Conclusions:

  • Elevated plasma Lp(a) levels are associated with impaired endothelium-dependent vasodilation.
  • This endothelial dysfunction occurs even in the absence of angiographically detectable atherosclerotic lesions.
  • These findings suggest Lp(a) contributes to endothelial dysfunction and may play a role in the development of atherosclerosis.
Abstract

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...